🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
163.26
-2.66 (-1.60%)
Nov 18, 2026, 2:33 PM EST - Market open
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

The portfolio now has three first-in-class medicines and Q3 sales annualizing at ~$4.5B. 2027 brings Phase III readouts for osavampator and direclidine, while INGREZZA is expected to grow through 2027-28 and face a manageable IRA impact in 2029.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Good morning, everyone. Really appreciate you joining us. My name is Akash Tewari. I head our pharma and biotech research efforts internally within Jefferies. I have the pleasure of hosting the Neurocrine management team. Very, very big 2027 catalyst slate for the company. You would argue maybe the most important in the company's history. A lot to talk about the pipeline, and also really the commercial portfolio as well. Very much looking forward to it. Kyle, why don't I hand it off to you for some intro remarks, and we will get started.

Kyle Gano
CEO, Neurocrine Biosciences

That would be great. Thanks, Akash, and thanks to Jefferies for the invitation. Really is great to be here. Maybe just to start things off here, I would like to also thank Jefferies for the following benefit of flying out here. For 10 hours, there was no Wi-Fi on our flight. I think those who know the benefit of that. No email, no MS Teams, no text messages from the family. It did give me a good opportunity to think, and I was thinking a lot about how much has changed at Neurocrine over the past couple years. When I stepped into the CEO role, we were a single-product company. That was just INGREZZA. Of course, we had a lot of ambition, and that ambition continues to this day. But fast-forward to Q3, we have got three first-in-class medicines and expanding portfolio.

If you look at just our Q3 performance, we are annualizing now at about $4.5 billion in sales. I learned a lot along the way over the past couple years as well. Diversification is a wonderful thing when you are talking about the commercial portfolio or the R&D pipeline, and I know we will get some questions, some Q&A on that. I have also learned that when you have three medicines versus one, you have a lot more to worry about. My family tells me that I perfected that part of the job over the past couple years. But all jokes aside, it has really been a pleasure working in this role and capacity at Neurocrine. I am pleased at the progress we have made over the past couple years, starting with INGREZZA in Q3, $800 million in sales. We had about 15% year-to-year growth, double-digit volume growth, record TRx, record NRx.

We raised our guidance for the second time. I can go on and on. But it really does speak to the strength of the brand and our team and the hard work that we put into INGREZZA over the past couple years. CRENNESITY, our second year into the launch. We have not completed the full second year, but we are annualizing at a rate now about $850 million in sales. Of the 20,000 patients that are out there in congenital adrenal hyperplasia, we have about 15%, a little bit more than 15% under care of CRENESSITY. You really can see a line of sight for us changing the standard of care. Then with VYKAT XR, we have added another important medicine to our portfolio that we think has the potential to be a really long-term, best-in-class medicine for patients with Prader-Willi syndrome. So we are looking to make good progress there in 2027.

But what's even more exciting to see is that we're not just growing. The business is becoming stronger. We are becoming a much more diversified one. Approximately 30% of our revenue comes from medicines other than INGREZZA. That would have been unheard of to think about just a few years ago. Then comes 2027. We have multiple phase II and phase III data readouts across our pipeline. Osavampator in MDD will read out phase III studies. Direclidine in schizophrenia will also read out phase III studies. These are potential medicines that are trajectory-changing for a company like Neurocrine. I think related to that, this year we have six new phase I starts, five new phase II starts. We've never been this productive from an R&D perspective in all of our history. So I think it paints a picture of a company that's evolving.

We're going to be having meaningful clinical data readouts as time moves along. That will be the norm, not the exception. So when I look back at all the progress that we've made, you really see a company that has a strong commercial foundation, has all the financial resources, and a really rich and diverse pipeline that will drive growth well into the future. So that literally is a flyby of the pipeline that came from sitting on the plane for 10 hours. I'm sure we can dive into some of the details now, but appreciate the opportunity.

Matt Abernethy
CFO, Neurocrine Biosciences

Hey, Kyle, before you do that, I have two value-added comments.

Kyle Gano
CEO, Neurocrine Biosciences

Sure.

Matt Abernethy
CFO, Neurocrine Biosciences

First, we are making forward-looking statements, so check out our SEC filings.

Kyle Gano
CEO, Neurocrine Biosciences

There you go.

Matt Abernethy
CFO, Neurocrine Biosciences

The second, I guess, value add is your team doesn't know that you're stressed, so that's a good thing.

Kyle Gano
CEO, Neurocrine Biosciences

That's very good.

Matt Abernethy
CFO, Neurocrine Biosciences

There you go.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

There we go. For the record, I never do work on flights. I am just sitting here watching rom-coms. Anyway, let us get started. I think over the last two years with INGREZZA, there have been moving parts, right? There is a, "Oh, wow, maybe we kind of underinvested in certain areas," and there has been the big push with Teva. There has been the IRA. There has been the advent, if you can call it that, of AUSTEDO XR and what that has done from a pricing perspective. So there have been moving parts with the VMAT2 class, but it definitely, since talking to, looking at Teva and their comments, but then also looking at your team, the error bars in terms of the commercial outlook for both products seems to have narrowed, and there seems to be increased visibility that maybe was not there in the last couple years.

Do those comments kind of resonate with you? I know you talked about 2027 pricing impact for INGREZZA on the Q3 call, but what is underlying that also seems to be a really healthy confidence on volume uptick. So do we feel like we have rebased in terms of the commercial trajectory? Let us know as we go out to the end of the decade, what is the CAGR of this product as it reaches maturity?

Kyle Gano
CEO, Neurocrine Biosciences

Well, maybe I will start, and then Matt, if you have some comments and thoughts there. I think you touched on a couple different things there, and maybe I will just share my general perspective on INGREZZA and the TD market. It is amazing to think that nine years in, we are still talking about a whole category that is growing in the mid-teens, and that is exactly what we have here. I think the underlying demand stems from the fact that TD itself, tardive dyskinesia, is a function of antipsychotic prescription volume and growth. That is the source and cause of TD, and that continues to grow at a clip of about 3% per year. There were 75 million prescriptions written last year, and that is a multiple of the growth rate of the general population.

So that is why you have seen us over the years have to update our prevalence numbers, because the denominator, the patient number, actually is increasing over time. So we have always felt like we have been trying to play catch-up here in the patients that are out there, diagnosing them, and then getting them under the care of INGREZZA. It has led us to have a couple sales force expansions, so those are some of the things that we have learned over the years. For the foreseeable future, antipsychotics are not going away. We think we have got maybe a different type of approach to treat patients that have diseases of psychosis with our muscarinics, but those are a few years out. Antipsychotics will continue to be a driving force for patients with these really debilitating diseases and conditions. So we have this underlying market that continues to grow.

INGREZZA fills that need there, and we think we've got a medicine that wins on clinical performance, ease of use, and even on price. That's what's been winning the day in terms of payers and healthcare providers over time. Now, what I would say about the dynamics of the marketplace itself is that for the longest time, it's been a two-product category where companies contract with plans, as we've seen in other disease states and conditions. Next year, we move into a new era, if you will, where the two brands are working in different places when it comes to that area. We have our competitor in this space, Teva, that is going to be entering their first year of the IRA using their maximum fair price that will be pulled in overall, and they'll have great access.

They'll have access to all the plans that they've been paying for over the past couple years. Neurocrine with INGREZZA, we will not be in an IRA moment. Ours happens in 2029. So it'll be a different era, if you will, for a two-year period. Over this timeframe, really what it comes down to still is access, and it's also share of voice. For us and Neurocrine, I think moving into this year, the question was, what is our access going to be like in 2027? Are we going to have to pay more for that access? As time has moved along, we've addressed that piece. What we would see moving forward is very similar access in 2027 and 2028 as we have this year. So very strong access. That comes with a bit of a price, net price per script, if you will.

There's some concessions that we have to pay for that. We also have a step-up in the statutory rebate that we pay for sales that go through Part D as a part of the Part D redesign in the IRA. But overall, that concession across those two metrics is going to be in the mid to single high digits, and that will be offset by the continued double-digit growth that we would expect on volume. So we'll be a net grower next year in terms of volume and a net grower next year in terms of revenue, and we would see something similar like that for 2028 as well. So overall, I think that's taken away a lot of the uncertainty, the error bars, if you will, as you said, for the next two-year period.

Then 2029 is our IRA moment, and we will begin discussions, negotiations, if you will, with CMS next spring, and that will conclude in the fall. Recall that we have the small biotech exemption that has a floor and a ceiling, 25%-34% off of a non-FAMP price that will help guide us through negotiations. But overall, 2029 is going to be a very manageable year. We call it a divot, not a hole or a cliff that we'll be seeing in that year, and we'll be able to then grow from that into the 2030s. So I think people are getting their hands around that, and that's very helpful for the business and allows us to focus on continuing investing in the brand and making it as big as it can be.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. Some very interesting comments there, particularly about IRA, because it is funny, you talk to investors and they are like, "Oh, Neurocrine is saying, 2029 and IRA." It almost sounds like the investor perception is the product goes X growth. That does not seem to be what you are saying. Even when we do our own work and you net out the AUSTEDO price increases as patients switch to XR, it still also seems like CMS was cognizant that this is a comorbid population, changes to access can have a meaningful downstream impact, and I feel like they were, let us say, pragmatic about what they were looking at from price concessions with an IRA perspective. This has been a point of uncertainty. Can you expand a bit more on that? Is INGREZZA going at growth post-2029, and really, how do we think about pricing impact that year?

Matt Abernethy
CFO, Neurocrine Biosciences

Yeah, the AUSTEDO outcome, I think is what you are alluding to, was, I would say for them, a favorable outcome, and I do think it reflects the value that it provides to patients as well as just understanding the dynamics of this patient population. For us, we do look at 2029 as being a manageable window of time. We know the error bars, to your earlier comment. The price negotiation that we are going to have is indexed to a - 25% to a - 34% discount off of something called non-FAMP. However, you stop paying the statutory rebate, which would have been 8% at that time, and you also are at a place where you are 100% on plans and covered. So when you think about the net implications to price, you can see yourself in a way to see that divot that Kyle articulated.

We do see the 2029 window is definitely not falling off a patent event. This is something that is going to have sustained durable revenue growth coming out of 2029.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Just saying that out loud. I know you were not discounting as much as AUSTEDO was maybe two years ago. But that has been part of the discussion over the last couple years, is the gross-to-net has improved as you try to get better access. In fact, I would probably guess you might be in the 25%-ish range. I know you may not comment. But then if you think about the small biotech exemption and the range in terms of what the price discount is off WAC, and then the offset in terms of the penalty getting offset on CPI, I could see a scenario where when you say manageable, I say no price impact. Would you go that far? Talk to us about some of the moving pieces.

Matt Abernethy
CFO, Neurocrine Biosciences

I'll say no.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Okay.

Matt Abernethy
CFO, Neurocrine Biosciences

Don't agree that you'd go that far. However, it's not as extreme as what people would have anticipated a few years ago, as you said. If you said IRA, for whatever reason, you thought of Neurocrine, and that's because our largest product, INGREZZA, has 70% of Medicare Part D. It's the mix of our underlying business. I do think there's going to be a significant offset to that 25%-34% decline. There are aspects, Akash, for example, that you have to think about best price for Medicaid and-

that fall into the Medicaid business as well. There are aspects that you have to more fully consider, but it is clearly more of a divot, then growing our cash flow significantly from there. As Kyle said, two of the points of consideration that people have had for INGREZZA or even for Neurocrine, how should you anticipate 2027 and 2028 when AUSTEDO has an MFP? I think we've cleared that hurdle. We have strong access. We'd expect that access to be continued into 2028, and 2028 to be more of a low single-digit price decline year. With the underlying volumes that we're seeing in the double-digit range, we're going to be positioned to be a multi-blockbuster medicine for many years ahead, with IP going out to 2038.

In addition to that, I'm sure we'll talk about it later, we do have a follow-on molecule that might lend itself to continue to expand and grow that market.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Actually, just to hit on that, because it does not come up enough in discussions. When we look at LAIs, they ended up. First of all, really unmet need in the market because it was a comorbid population that really does struggle with adherence. It took 15%-20% market share. I could argue that when we look at tardive dyskinesia, it is just as high of an unmet need to actually get longer-acting formulations. What data are we going to get in 2027 with the next-gen VMAT2s, and how quickly could we move to a long-acting paradigm? Can you comment a bit about the unmet need that a long-acting therapy could provide based on your market research?

Kyle Gano
CEO, Neurocrine Biosciences

Well, maybe I will start, and then Eiry can fill in some of the details here. One of the things that I am excited about the LAI technology is, in approach, is that we hear from physicians when we have our ad boards, other discussions about INGREZZA, that one of the unmet needs out there is a long-acting injectable. I think we have seen significant adoption of this type of approach for patients, in particular in the psychiatry side, over the past couple years with antipsychotics showing success there. We know that there are patients out there not getting INGREZZA, an oral once-daily medicine, because the physician is concerned that they will not stay on it once they leave their care.

Having a long-acting injectable, I think, will open up a new side of the business that we have not been able to tap into yet. I think that is a really positive thing to think about when we look at our next-generation molecules that we are building and developing. I think the other piece of it is just, it is a space in general that is not being satisfied out there, even amongst those patients that are taking our medicine today. I think there are multiple opportunities out there when we think about expanding the market. I do not think we will get there with INGREZZA, given the total daily dose that is attached to it, but our next-generation molecules were specifically designed to address this issue. In terms of the data and timing, I will let Eiry talk about that.

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

Yeah. You are alluding to NBI-'890, which is our first of several next-generation VMAT2 inhibitors that we have, with two of those being in the clinic right now. The data from the phase II dose-finding study for NBI-'890 read out in the middle of next year. I mean, that molecule was designed to have the higher potency, so we are testing lower doses in that study than the 40 and 80 that we have for INGREZZA. In addition, the molecule was chosen on other differentiating features of no 2D6 metabolism.

Also potentially a longer half-life in the context of that oral treatment, and moving away from the QT liability that's been associated with previous VMAT2 inhibitors. As we read out the data next year, those dosing information will inform the formulation work and the work on the LAI. Then, what you'll see is us moving forward into phase III development, registration development for the oral first, and then in a somewhat staggered path, we will be bringing forward the LAI with the technology that makes most sense. Because we have to have both the oral and the LAI available.

Which kind of gives one-stop shopping for a single molecule approach. Patients usually get stabilized on the oral first and then move to the LAI for consistent follow-up therapy.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Let me ask a dual-part question. A, as you improve half-life with your oral and then also LAI, is there a potential for improved efficacy with VMAT2? Is there a thesis there? And kind of lateral bridge, you have a next-gen CRENESSITY, which will also have data next year. Is the improvement not just convenience, but is there potentially an efficacy improvement that could be had as you go to weekly?

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

Yeah, speaking to the VMAT2 class, I mean, one of the things we know about this class of medicine, although we've seen adherence levels that have been significantly higher than the antipsychotics, we do know that compliance is still an issue with any oral therapy in there. And that does, given what we see with the rapid onset of activity of the VMAT2 inhibition in helping tardive dyskinesia, but rapid loss of efficacy if you take the drug away, then one could anticipate that you would see more consistent efficacy over a longer period of time with the LAI. Same could be true also for CRENESSITY. What I will say, though, is that both those first medicines have set a high bar with respect to what we've seen in efficacy already.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Right.

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

I think that's an important feature.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Understood. Coming a bit on CRENESSITY, and it's one of these things where you have to disprove a negative, right? Vertex will have their data, let's say, in the next year and a half. We'll see how quickly that trial rolls out. I do think, like, the data's impressive. There's safety questions that will get answered with data. But there is, I think, an investor perception that, well, once Vertex goes on the market, I just don't know how to model CRENESSITY. Does CRENESSITY go, like, the revenue growth flat lines, and we really have a mature product? That doesn't seem to be how your team talks about it. You alluded that CRENESSITY really could become standard of care. As competition enters the market from Vertex, are you confident that you could still see continued growth in the CRENESSITY franchise?

Do you think that an additional competitor maybe expands the market, or do you think it actually will have an impact on your growth trajectory?

Kyle Gano
CEO, Neurocrine Biosciences

Well, I think that always having multiple companies out there with products is going to help accelerate penetration of market, helping more patients. You can't help but appreciate the benefits of that. I really like our approach that we have with CRENESSITY, however. The way that we're tackling the disease is we're working upstream, trying to control the HPA axis. That's the basic struggle the body has in CAH. The way that, up until CRENESSITY, that patients, families with children with CAH have tried to address it was by using super physiological doses of GCs, glucocorticoids.

What CRENESSITY allows them to do is capture, recapture the HPA axis for the first time, and it's the only approach in development, whether you're talking about CRENESSITY or even our next-generation medicine, that allows patients to reduce and control ACTH, which is a hormone that agonizes all melanocortin receptors in all tissues, not just on the adrenal gland. It also helps reduce and normalize androgens, or A4, and it helps reduce excessive use of GCs. So it hits all facets of the disease. It's the only approach that does that. Ultimately, we think that will continue to drive the long-term data outcomes that we've seen with CRENESSITY. Last year, we shared that ENDO two-year data in children and adults. This year will be three years of data and four years and so forth.

We're always going to be in a leadership position to show the benefits of long-term treatment of our medicine, helping with ACTH, A4, and glucocorticoid dose reduction. We think that's going to ultimately give us the opportunity to be a long-term grower here overall in terms of penetrating the market of patients with CAH as well as revenue. The last thing I would say with our long-term data is that we definitely have a significant advantage in terms of pediatric data, in terms of an indication that takes patients, or allows patients all the way down to four to start on treatment. We have a study ongoing now that will allow us to treat patients all the way down to just a few months old. That's probably the right way to think about the disease, treating patients very early, very young.

You can change the whole trajectory of their disease. That's what we've seen play out commercially thus far, is that the vast majority of patients have been on the children, the adolescent side of things. You can change their growth trajectories. You can reduce their long-term exposure to glucocorticoid s at a very young age, and the benefits of that will only compound over time. I think we have a lot of things that we like in our approach. I would say, whether it's a competitor to Neurocrine or our next-generation program, CRENESSITY set a very high bar.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Right. Understood. Going into the pipeline as we end the discussion, we hit on osavampator. We're seeing, I think, an amazing transformation as psychedelics have really had You've seen several successful phase III studies in this kind of treatment-resistant late-stage depression. I feel like there is always so much risk on MDD studies, but it does seem like giving a psychedelic, it's potent. I think that's part of the story. There's no doubt it's a potent MOA, but there's an element of staying inpatient from phase II to phase III and controlling variables, whether it's site selection, making sure the studies aren't too large, which may apply not just to psychedelics, but really even apply to your program as well.

Can you talk about the mistakes or the lessons you've learned in terms of MDD development in the field, and what is unique about the three phase III studies that you have reading out with osavampator next year?

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

Yeah. Couple of comments first. First, just one brief comment about psychedelics. I think obviously we have seen efficacy. At the end of the day, it's about benefit risk, though, and also about how that medicine gets delivered and how it fits into the treatment paradigm. I think that's still an area that's yet to be worked out. For osavampator, just a few, that's an AMPA positive allosteric modulator. I think we have several reasons for confidence, and then I'll talk about the phase III program. The first is obviously this is a validated target. Actually, ketamine is part of what validates this target, working through glutamate to activate AMPA. We activate AMPA directly, so we avoid the glutamatergic surge and the psychotomimetic side effects that you see with a lot of these medicines, not just esketamine and ketamine.

When we look at our phase II data, we also have a high level of confidence around the data that read out. We saw a large effect size, average placebo response, and so confidence in moving forward with that dose. What we did in moving from phase II to phase III, based on learnings from other programs, was first of all, we kept the program very, very simple.

We know that things that drive placebo response in MDD trials are, first of all, the number of active arms, so the percentage of people who believe they are on active treatment and the investigator believes they're on active treatment. We kept that to 50/50, so that's the best kind of scenario to do that in. The second is the size of the trial. The larger the trial, because of more sites, because of more variability, the harder it is to get a positive outcome. Our trial size in phase III is the same as our phase II trial size, 200 patients per trial. That's why we did three rather than two, to give us an extra shot on goal there.

The next thing is oversight of the investigative sites, and that starts from the very beginning with having as small a number of investigative sites as you can to minimize variability. Appropriate oversight of training of those sites, ensuring that we're getting high-quality investigators who are trained appropriately to get high-quality patients into the study. The last piece in that oversight, just briefly I'll mention, is that the neuropsych division of the FDA encourages this input. Others do not. Other divisions do not. We have an ongoing blinded data review of data as it's generated from individual site level and across the study.

As investigators start to enroll patients, we're looking at the curves that they're generating, both in terms of the nature of the screening for patients, but also the shape of the MADRS curves that are generated. We have intervened and stopped sites, retrained sites, or given sites additional go-ahead on the basis of that quality. That's pretty much what we're doing at an operational level. At the end of the day, obviously the medicine has to perform, and these are higher risk areas. We're very excited about the prospect of reading out those trials in the second half of next year.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

If I'll sneak in one more, I know we're over, but what can you comment about what you've seen on a blinded basis in terms of site conduct? I know this is probably stuff Samir's been running around

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

Yep, yeah. A lot of

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

on sites in Florida.

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

A lot of our team actually are running around at the site level and ensuring that quality. I think we're pleased in general. It's a very, very intensive activity. What I can say as well, just as we look at blinded data, the other way we do that is looking at safety data on an ongoing basis.

We've had several data safety monitoring board reviews, no changes in the program on the basis of that. Another thing that gives us confidence from a kind of tolerability safety point of view, very low dropout rate from that program in phase III from the short-term studies, and a very high, greater than 90% rollover into the open-label extension, which again speaks well to the-

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

You're already in open-label extension with some of your phase IIIs?

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

I'm sorry?

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

You're already in open-label-

Eiry Roberts
Chief Medical Officer, Neurocrine Biosciences

Oh, yeah. Yeah.

Akash Tewari
Head of Pharma and Biotech Research, Jefferies

Don't think that's well understood. On that note, I really appreciate it. It was a great conversation. Thanks so much, everyone.

Kyle Gano
CEO, Neurocrine Biosciences

Thanks, Akash.